期刊文献+

Multiple sclerosis: New insights and trends 被引量:1

Multiple sclerosis: New insights and trends
下载PDF
导出
摘要 Multiple sclerosis(MS) is the most famous autoimmune disease attacking the central nervous system. It attacks people from age 20–50 years old and the females' attacks double than males' attacks. MS is an autoimmune disease affecting principally the central nervous system that cause nerve sheath demyelination followed by axon damage and paralysis. MS symptoms include muscle weakness, weak reflexes, muscle spasm, difficult in move, miss-coordination and unbalance with others. There are many factors may be responsible for MS: microbial, viral, smoking, stress, environmental toxins, contaminated diet, and gout. MS is wide spread in the populations in North Europe and this related to lack of vitamin D due to decrease of sunlight exposure. MS biomarkers include nitric oxide, interleukin-6, nitric oxide synthase, fetuin-A and osteopontin. MS is not a genetic disease where MS occurs when human leukocyte antigen system related genes are changed in chromosome 6. The physiology of MS is monitored by activation of immuneinflammatory, oxidative, and nitrosative stress pathways. MS is including two main steps:(1) myelin sheath destruction and formation of lesions and,(2) inflammation. Four types of MS can be distinguished: relapsing-remitting, primary progressive, secondary progressive and progressive relapsing. Nine treatments have been accepted for relapsingremitting MS type: interferon b-1a, interferon b-1b, mitoxantrone, natalizumab, glatiramer acetate, fingolimod, dimethyl fumarate, teriflunomide, and alemtuzumab, however,the only treatment used is mitoxantrone for progressive MS but many of MS treatments side effects are recorded. Complementary treatments also used in MS treatments such as:vitamin D, Yoga, medicinal plants, oxygen therapy, acupuncture and reflexology. Multiple sclerosis (MS) is the most famous autoimmune disease attacking the central nervous system. It attacks people from age 20–50 years old and the females' attacks double than males' attacks. MS is an autoimmune disease affecting principally the central nervous system that cause nerve sheath demyelination followed by axon damage and paralysis. MS symptoms include muscle weakness, weak reflexes, muscle spasm, difficult in move, miss-coordination and unbalance with others. There are many factors may be responsible for MS:microbial, viral, smoking, stress, environmental toxins, contaminated diet, and gout. MS is wide spread in the populations in North Europe and this related to lack of vitamin D due to decrease of sunlight exposure. MS biomarkers include nitric oxide, interleukin-6, nitric oxide synthase, fetuin-A and osteopontin. MS is not a genetic disease where MS occurs when human leukocyte antigen system related genes are changed in chromosome 6. The physiology of MS is monitored by activation of immune-inflammatory, oxidative, and nitrosative stress pathways. MS is including two main steps:(1) myelin sheath destruction and formation of lesions and, (2) inflammation. Four types of MS can be distinguished: relapsing-remitting, primary progressive, secondary pro-gressive and progressive relapsing. Nine treatments have been accepted for relapsing-remitting MS type: interferon b-1a, interferon b-1b, mitoxantrone, natalizumab, glatir-amer acetate, fingolimod, dimethyl fumarate, teriflunomide, and alemtuzumab, however, the only treatment used is mitoxantrone for progressive MS but many of MS treatments side effects are recorded. Complementary treatments also used in MS treatments such as:vitamin D, Yoga, medicinal plants, oxygen therapy, acupuncture and reflexology.
出处 《Asian Pacific Journal of Tropical Biomedicine》 SCIE CAS 2016年第5期429-440,共12页 亚太热带生物医学杂志(英文版)
关键词 Multiple SCLEROSIS Diagnosis GENETICS PHYSIOLOGY TREATMENTS Multiple sclerosis Diagnosis Genetics Physiology Treatments
  • 相关文献

参考文献133

  • 1Hsieh Kevin Li-Chun,Stefan Schob,Matthias W.G. Zeller,Benjamin Pulli,Muhammad Ali,Cuihua Wang,Terry Ting-Yu Chiou,Yuk-Ming Tsang,Po-Shun Lee,Thomas P. Stossel,John W. Chen.??Gelsolin decreases actin toxicity and inflammation in murine multiple sclerosis(J)Journal of Neuroimmunology . 2015
  • 2Chamini J. Perera,Justin G. Lees,Samuel S. Duffy,Preet G.S. Makker,Brett Fivelman,Vasso Apostolopoulos,Gila Moalem-Taylor.??Effects of active immunisation with myelin basic protein and myelin-derived altered peptide ligand on pain hypersensitivity and neuroinflammation(J)Journal of Neuroimmunology . 2015
  • 3Beatrice Macchi,Francesca Marino-Merlo,Ugo Nocentini,Valerio Pisani,Salvatore Cuzzocrea,Sandro Grelli,Antonio Mastino.??Role of inflammation and apoptosis in multiple sclerosis: Comparative analysis between the periphery and the central nervous system(J)Journal of Neuroimmunology . 2015
  • 4Torabi, Mahmoud,Green, Chris,Yu, Nancy,Marrie, Ruth Ann.??Application of Three Focused Cluster Detection Methods to Study Geographic Variation in the Incidence of Multiple Sclerosis in Manitoba, Canada(J)Neuroepidemiology . 2014 (1)
  • 5G. Petersen,R. Wittmann,V. Arndt,D. G?pffarth.??Epidemiologie der Multiplen Sklerose in Deutschland(J)Der Nervenarzt . 2014 (8)
  • 6Fred D. Lublin,Stephen C. Reingold,Jeffrey A. Cohen,Gary R. Cutter,Per Soelberg S?rensen,Alan J. Thompson,Jerry S. Wolinsky,Laura J. Balcer,Brenda Banwell,Frederik Barkhof,Bruce Bebo,Peter A. Calabresi,Michel Clanet,Giancarlo Comi,Robert J. Fox,Mark S. Freedman,Andrew D. Goodman,Matilde Inglese,Ludwig Kappos,Bernd C. Kieseier,John A. Lincoln,Catherine Lubetzki,Aaron E. Miller,Xavier Montalban,Paul W. O?Connor,John Petkau,Carlo Pozzilli,Richard A. Rudick,Maria Pia Sormani,Olaf St.??Defining the clinical course of multiple sclerosis: The 2013 revisions(J)Neurology . 2014 (3)
  • 7Lawrence Steinman.??Immunology of Relapse and Remission in Multiple Sclerosis(J)Annual Review of Immunology . 2014
  • 8Kerstin Berer,Gurumoorthy Krishnamoorthy.??Microbial view of central nervous system autoimmunity(J)FEBS Letters . 2014
  • 9Marcus W. Koch,Luanne M. Metz,Smriti M. Agrawal,V. Wee Yong.??Environmental factors and their regulation of immunity in multiple sclerosis(J)Journal of the Neurological Sciences . 2013 (1-2)
  • 10Pozuelo-moyano, Beatriz,Benito-le?n, Juli?n,Mitchell, Alex J,Hern?ndez-gallego, Jes?s.??A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Trials Examining the Clinical Efficacy of Vitamin D in Multiple Sclerosis(J)Neuroepidemiology . 2013 (3)

同被引文献22

引证文献1

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部